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Introduction
Two genes mutated in autosomal recessive cases of Parkin-
son’s disease, PINK1 (Valente et al., 2004) and Parkin (Kitada 
et al., 1998), have been found to work in the same pathway 
(Clark et al., 2006; Park et al., 2006; Yang et al., 2006) linked 
to mitochondrial maintenance (Greene et al., 2003; Palacino 
et al., 2004; Gautier et al., 2008). PINK1 is a kinase local-
ized to mitochondria (Valente et al., 2004), whereas Parkin is 
an E3 ubiquitin ligase located in the cytosol (Shimura et al., 
1999; Shimura et al., 2000). Upon mitochondrial damage or 
uncoupling, Parkin relocalizes to mitochondria and can me-
diate  the  autophagic  elimination  of  damaged  mitochondria 
(Narendra et al., 2008), which is dependent on PINK1 kinase 
activity (Geisler et al., 2010; Matsuda et al., 2010; Narendra 
et al., 2010; Vives-Bauza et al., 2010). These results suggest 
that PINK1 and Parkin may normally participate in a mito-
chondrial quality control pathway that is defective in certain 
familial forms of Parkinson’s disease.
How PINK1 recruits Parkin to damaged mitochondria   
is unclear. Although endogenous PINK1 protein expression is 
constitutively low owing to rapid turnover, PINK1 proteolysis 
is inhibited by mitochondrial uncoupling, allowing a robust 
increase in expression when a mitochondrion is damaged and 
loses membrane potential (Lin and Kang, 2008; Matsuda et al.,   
2010; Narendra et al., 2010). The protease that mediates this 
constitutive PINK1 turnover is unknown. Rhomboid-7 was re-
ported to be necessary for PINK1 cleavage and activity in Dro-
sophila melanogaster cells (Whitworth et al., 2008). However, 
Rhomboid-7 is localized to the inner mitochondrial membrane 
(Hill and Pellegrini, 2010), whereas ectopic and endogenous 
PINK1 have been reported to span the outer mitochondrial mem-
brane with the C-terminal kinase region facing the cytosol poised 
to induce Parkin translocation (Zhou et al., 2008; Narendra et al.,   
2010). However, PINK1 has an apparent N-terminal mitochon-
drial import sequence predicted to mediate import through the 
TIM23 complex either to the matrix or spanning the inner mem-
brane. Consistent with a predicted interaction between PINK1’s   
N terminus and the TIM23 import machinery, PINK1’s N terminus   
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to  recruit  cytosolic  Parkin  to  mitochondria  to  mediate 
mitophagy in mammalian cells. Although PINK1 has a 
predicted mitochondrial import sequence, its cellular and 
submitochondrial localization remains unclear in part   
because it is rapidly degraded. In this study, we report that 
the  mitochondrial  inner  membrane  rhomboid  protease 
presenilin-associated  rhomboid-like  protein  (PARL)  me-
diates cleavage of PINK1 dependent on mitochondrial 
membrane potential. In the absence of PARL, the con-
stitutive degradation of PINK1 is inhibited, stabilizing a 
60-kD  form  inside  mitochondria.  When  mitochondrial 
membrane potential is dissipated, PINK1 accumulates as 
a 63-kD full-length form on the outer mitochondrial mem-
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absent, and a 60-kD predicted MTS-PINK1 (Fig. 1 c, orange 
arrowhead) was stabilized, suggesting that PARL-mediated prote-
olysis normally generates the 52-kD fragment. Rhomboid proteases 
such as PARL cleave proteins in and around membrane-spanning 
domains (Urban et al., 2001; Sík et al., 2004; Strisovsky et al., 
2009). PARL-mediated cleavage of PINK1 in the predicted 
membrane-spanning domain between residues 94 and 110 would 
yield a protein fragment of 52 kD, which is consistent with 
the molecular mass of the fragment stabilized by MG132 and 
absent in the PARL KO MEFs.
To further analyze the effect of PARL on PINK1 cleav-
age, we performed in vitro mitochondrial import assays. Mito-
chondria freshly isolated from WT and PARL KO MEFs were 
incubated with 
35S-labeled PINK1 in the presence or absence of 
CCCP. After import, each sample was split in two and treated 
with or without 5 µg/ml proteinase K (PK) to degrade non-
imported protein (Fig. 1 d). The 52-kD species of PINK1 was 
found to accumulate in WT MEF mitochondria (Fig. 1 d, red 
arrowheads) but was absent in PARL KO samples, corroborating   
that PARL-mediated proteolysis generates the 52-kD form. As in 
PARL KO cells (Fig. 1 c), mitochondria isolated from PARL KO 
MEFs did not generate the 52-kD fragment but yielded a new 
60-kD species of PINK1 predicted to be MTS-PINK1 (Fig. 1 d,   
orange  arrowheads).  Generation  of  both  the  52-kD  form  of 
PINK1 in WT mitochondria and the 60-kD form of PINK1 in 
PARL KO mitochondria was prevented by CCCP, indicating that 
they required inner mitochondrial membrane import (Fig. 1 d). 
When we incubated the mitochondria containing imported 
35S-labeled PINK1 with PK, the 60-kD MTS-PINK1 in PARL 
KO mitochondria and the 52-kD PINK1 in WT mitochondria 
were more stable than FL PINK1 (Fig. 1 d, bottom). These re-
sults suggest that in contrast to FL, the CCCP-stabilized form of 
PINK1 that localizes to the outer mitochondrial membrane facing 
the cytosol (Narendra et al., 2010), the 60-kD MTS-PINK1, 
which appears in the absence of PARL, and the 52-kD PINK1 
are protease-protected within polarized mitochondria (Fig. 1 d).
To confirm that MTS-PINK1 reflects a form imported 
into the mitochondria to allow MPP cleavage, we compared 
PK sensitivity after import of radiolabeled PINK1 relative to 
control proteins in the outer mitochondrial membrane and inter-
membrane space (Fig. 1 e). FL, radiolabeled PINK1 (Fig. 1 e, blue 
arrowhead) and Tom20 were rapidly degraded by 100 µg/ml 
PK treatment, whereas MTS-PINK1 ((Fig. 1 e, orange arrow-
head), intermembrane space protein Htra2/Omi, and matrix pro-
tein Hsp70 were more stable.
We have previously shown that experimentally stabilized 
PINK1 on the mitochondrial outer membrane recruits Parkin 
even  in  the  absence  of  mitochondrial  uncoupling  (Narendra   
et al., 2010). Therefore, if MTS-PINK1 is sequestered within the 
mitochondria, as indicated in Fig. 1 (d and e), it would not be 
positioned to recruit Parkin. Indeed, when we transfected HeLa 
cells stably overexpressing YFP-Parkin with scrambled control 
siRNA or siRNA for PARL as in Fig. 1 a, no mitochondrial 
translocation of Parkin was observed (Fig. 1 f). Supporting this 
conclusion, the 60-kD form of MTS-PINK1 stabilized in cou-
pled mitochondria in the absence of CCCP in PARL KO MEFs 
fails to recruit mCherry-Parkin to mitochondria (Fig. 1 g).
is sufficient to target ECFP to the matrix (Silvestri et al., 2005), 
and deletion of PINK1’s putative transmembrane domain results 
in targeting of its kinase domain to the matrix (Zhou et al., 2008). 
Finally, in some studies, PINK1 has been localized to the inner 
membrane with its kinase domain facing the intermembrane 
space (Silvestri et al., 2005; Plun-Favreau et al., 2007; Pridgeon 
et al., 2007). As these previous studies were performed in the 
absence of uncouplers that were recently found to influence 
PINK1 stability, it remains unclear how and where endogenous 
PINK1 is degraded.
Results and discussion
Presenilin-associated rhomboid-like protein 
(PARL) is required for proteolytic cleavage 
of PINK1
To identify the protease mediating PINK1 turnover on mito-
chondria,  we  knocked  down  known  mitochondrial  proteases 
by siRNA and examined the PINK1 expression pattern. We 
found that in contrast to siRNAs against Afg3L2, ClpP, Oma1, 
HtrA2/Omi, Paraplegin, and Yme1 (unpublished data), siRNA 
for PARL led to increased expression of endogenous PINK1 
in the absence of the depolarizing agent carbonyl cyanide-m- 
chlorophenyl hydrazone (CCCP; Fig. 1 a). In addition, the mo-
lecular mass of the PINK1 band (Fig. 1 a, orange arrowhead) 
in the absence of CCCP was slightly lower than that of endog-
enous PINK1 stabilized by CCCP, predicted to represent full-
length (FL) PINK1 (63 kD; Fig. 1 a, blue arrowhead) based on 
molecular mass. The 60-kD band would be consistent with 
the molecular mass of PINK1 with a mitochondrial targeting se-
quence  (MTS)  deleted  (MTS)  after  mitochondrial  processing 
protease (MPP) cleavage (Fig. 1 a). When mitochondria were   
uncoupled with CCCP, both scrambled siRNA– and PARL 
siRNA–transfected cells showed the same level of FL PINK1 ac-
cumulation, indicating that knockdown of PARL did not affect 
PINK1 expression in uncoupled mitochondria. This contrasts with 
our previous work using short hairpin RNAi targeting a differ-
ent site in PARL mRNA that was interpreted to exclude PARL 
as a protease for PINK1 cleavage, likely owing to insufficient 
knockdown of endogenous PARL in HeLa cells and to insufficient 
expression of ectopic PINK1 in PARL knockout (KO) mouse 
embryonic fibroblasts (MEFs; Narendra et al., 2010). To confirm 
the effect of PARL knockdown on endogenous PINK1 cleavage, 
we analyzed MEFs derived from wild-type (WT) or PARL KO 
mice. Given that we could not detect endogenous mouse PINK1 
in MEF cells, cells were transfected with a human PINK1-V5/
His construct. Consistent with the results observed in HeLa cells 
for endogenous PINK1, PARL KO MEFs displayed a 60-kD 
form of PINK1, likely to be MTS-PINK1, in the absence of 
CCCP (Fig. 1 b, orange arrowhead).
Treatment of cells with a proteosome inhibitor stabilizes 
a 52-kD PINK1 fragment (Lin and Kang, 2008; Zhou et al., 
2008), suggesting that proteosome-independent proteolysis yields 
a 52-kD form of PINK1 that is subsequently degraded by the 
proteosome (Narendra et al., 2010). When we treated PARL KO 
MEFs transiently overexpressing PINK1-V5/His with MG132, 
the 52-kD fragment of PINK1 (Fig. 1 c, red arrowhead) was   935 m-dependent cleavage of PINK1 mediated by PARL • Jin et al.
Figure 1.  Constitutive cleavage of PINK1 is mediated by PARL. (a) HeLa cells were transfected with scrambled control siRNA or PARL siRNA. After 4 h 
incubation with or without 10 µM CCCP, mitochondria were isolated, and mitochondrial protein extracts were assayed for endogenous levels of PINK1 
and PARL by immunoblotting. VDAC1 is a mitochondrial marker. (b) MEFs from PARL WT and KO mice were transfected with PINK1-V5/His for 2 d and 
treated with DMSO or 10 µM CCCP for 4 h. Exogenous PINK1 levels were assayed by immunoblotting. Tubulin is a loading control. (c) PARL WT and   
KO MEFs were transfected with PINK1-V5/His as in b and treated with DMSO or 10 µM MG132. After 4 h of treatment, cells were fractionated, 
and exogenous PINK1 levels in mitochondrial fraction were measured with immunoblotting. VDAC1, mitochondrial loading control. (d) [
35S]methionine- 
labeled PINK1 was incubated for different times with mitochondria isolated from PARL WT or KO MEFs in the presence or absence of 1 µM CCCP. After 
import, samples were treated with or without 5 µg/ml PK. Radiolabeled PINK1 was detected using digital autoradiography. Asterisks, nonspecific bands.   
(e) [
35S]-PINK1 was imported into PARL KO mitochondria for 60 min as in d, and these mitochondria were incubated in the presence or absence of high PK 
(100 µg/ml) for 10 min. Hsp70, Htra2/Omi, and Tom20 were identified by immunoblotting as markers for mitochondrial matrix, inter membrane space, 
and outer membrane, respectively. (f) HeLa cells stably expressing YFP-Parkin were transfected with control (siCtrl) or PARL siRNA (siPARL) for 192 h. After 
transfection, cells were treated with either DMSO or 10 µM CCCP for 1 h, stained with TMRE, and analyzed by live cell imaging. Bars, 20 µm. (g) PARL 
WT and KO MEFs transfected with PINK1-YFP and mCherry-Parkin were treated with 10 µM DMSO or CCCP for 3 h. Cells (≥50/treatment) were counted 
for mitochondrial translocation of Parkin. Counting results were represented as mean ± SEM from four replicates. Blue arrowheads, FL PINK1; orange   
arrowheads, MTS-PINK1; red arrowheads, 52-kD PINK1.JCB • VOLUME 191 • NUMBER 5 • 2010   936
in the mitochondrial fraction but not in the cytosolic fraction. 
Mitochondrial fractions subjected to alkaline (Na2CO3) extrac-
tion yielded FL (Fig. 2 b, blue arrowhead) and 52-kD (Fig. 2 b,   
red arrowhead) PINK1 in the pellet fraction, suggesting that 
both forms of PINK1 are integrated within mitochondrial mem-
branes. To determine whether FL and 52-kD PINK1 exist in the 
same submitochondrial compartment, we conducted a PK pro-
tection assay. Although FL PINK1 (Fig. 2 c, blue arrowhead) 
was rapidly degraded by low concentrations of PK (1 µg/ml), 
the 52-kD PINK1 (Fig. 2 c, red arrowhead) was very stable 
and could be detected even after incubation with 100 µg/ml PK   
(Fig. 2 c), indicating that endogenous FL PINK1 and 52-kD 
PINK1 are in different compartments, corroborating the in vitro 
import results shown in Fig. 1 d. We addressed the activity of 
endogenous 52-kD PINK1 to recruit Parkin. When we treated 
HeLa cells stably expressing YFP-Parkin with MG132 for 8 h to 
accumulate the 52-kD PINK1 (Fig. 1 c; Narendra et al., 2010), 
we detected no mitochondrial translocation of Parkin (Fig. 2 d),   
A mutant form of PINK1 lacking the transmembrane re-
gion in PINK1 between amino acids 91 and 117 does not accu-
mulate in cells upon CCCP treatment (Fig. S1, a and b) and does 
not function to recruit Parkin after CCCP treatment in marked 
contrast to WT PINK1 (Fig. S1 c). Thus, the transmembrane 
domain appears to be essential for proper positioning of WT 
PINK1 in the outer mitochondrial membrane to recruit Parkin.
Although overexpressed PINK1 accumulates as a 52-kD 
form in the cytosol after proteosome inhibition (Muqit et al., 
2006; Tang et al., 2006; Lin and Kang, 2008; Takatori et al., 
2008; Weihofen et al., 2008), the location and topology of the 
endogenous 52-kD PINK1 produced by PARL-mediated prote-
olysis has not been conclusively elucidated. To address this, we 
treated cells first with MG132 to accumulate the 52-kD PINK1 
followed by treatment with CCCP to accumulate FL 63-kD 
PINK1 to compare the localization of the two proteins in the 
same samples. Endogenous FL PINK1 (Fig. 2 a, blue arrow-
head) and 52-kD PINK1 (Fig. 2 a, red arrowhead) were detected 
Figure 2.  The 52-kD form of endogenous PINK1 is found inside mitochondria and does not recruit Parkin. (a) HeLa cells were initially treated with 50 µM 
MG132 for 10 h and then together with 10 µM CCCP for a final 3 h. Cells were fractionated and analyzed by immunoblotting using antibodies against the 
indicated proteins. (b) The mitochondrial fraction from panel a was subjected to alkaline extraction using sodium carbonate and immunoblotted for PINK1, 
Cyt c, and Tim23. (c) Mitochondria from panel a were incubated for 30 min on ice with various concentrations of PK followed by immunoblotting using 
antibodies against PINK1 and the indicated mitochondrial markers. (d) HeLa cells stably expressing YFP-Parkin were treated with DMSO, 10 µM CCCP, or 
10 µM MG132 for 3 h followed by staining with TMRE and confocal imaging. Bars, 20 µm. Blue arrowheads, FL PINK1; red arrowheads, 52-kD PINK1.937 m-dependent cleavage of PINK1 mediated by PARL • Jin et al.
proteolytic activity. To further investigate the submitochondrial 
location of PINK1-YFP R98F, we performed immunostaining 
of fixed cells that were either untreated or permeabilized with 
0.005% digitonin or 0.25% Triton X-100. Control experiments 
showed that this assay could distinguish between mitochon-
drial proteins localized inside (cytochrome c [Cyt c]) or out-
side (Tom20) of the mitochondrial outer membrane (Fig. 4 b).   
HeLa cells transfected with WT PINK1-YFP followed by 
treatment with CCCP for 3 h showed positive immunostaining 
in all cells expressing PINK1-YFP after permeabilization with 
0.005% digitonin. However, anti-GFP immunoreactivity was 
absent in most HeLa cells transfected with R98F PINK1-YFP 
using the same permeabilization conditions, indicating that 
the C terminus of PINK1-YFP R98F is protected by the mito-
chondrial outer membrane in the absence of CCCP treatment   
(Fig. 4, c and d).
Consistent with localization within mitochondria, expres-
sion of R98F PINK1-YFP did not induce mitochondrial translo-
cation of mCherry-Parkin in HeLa cells (Figs. 4 e and S3 b) or 
PINK1 KO cells (Fig. 4 f). CCCP treatment of PINK1 KO cells 
expressing R98F PINK1-YFP induced Parkin translocation, in-
dicating that this mutant is functional for inducing Parkin trans-
location when located on the outer mitochondrial membrane.
Interestingly, in the screen for PINK1 mutants displaying 
incomplete PARL-mediated cleavage, we also identified A103W 
and G105W mutations that instead stabilize the 52-kD fragment 
of PINK1 (Fig. 3 b, red arrowheads and blue rectangles) in the 
absence of MG132 treatment. Using differential permeabiliza-
tion conditions described in Fig. 4 b, both A103W and G105W 
PINK1 mutants were protected by the mitochondrial outer mem-
brane and did not recruit Parkin to mitochondria in HeLa cells 
or PINK1 KO MEFs (not depicted).
In coupled mitochondria, PINK1 appears to be guided to 
mitochondria by the N-terminal targeting sequence after trans-
lation and imported into the inner mitochondrial membrane via 
the general mitochondrial import machinery, TOM and TIM23 
complexes (Fig. 5). In this study, it would encounter MPP, 
which cleaves the MTS for most MTS-containing mitochondrial 
proteins to generate a 60-kD MTS-PINK1. PINK1 appears 
to be cleaved to a 52-kD form within the inner mitochondrial 
membrane by PARL-mediated proteolytic activity. The 52-kD 
PINK1 is then degraded by an MG132-sensitive protease. Thus, 
a prominent function of PARL in the PINK1–Parkin pathway 
appears to be facilitating the rapid degradation of PINK1 by 
mediating the cleavage of PINK1 in the mitochondrial inner 
membrane. The PARL KO mouse displays defects in postnatal 
growth and lifespan (Cipolat et al., 2006) that may in part be 
caused by accumulation of MTS-PINK1 in the mitochondrial 
inner membrane space.
Our results indicate that a protein with an MTS can be dif-
ferentially targeted to inner and outer mitochondrial membranes 
depending on the presence of mitochondrial membrane potential 
and may explain the discrepancies regarding PINK1 location in 
the literature. In yeast, a bipartite targeting sequence of NADH 
cytochrome B5 reductase (Mcr1p) drives it to the mitochon-
drial inner membrane, where it is cleaved and released into the   
intermembrane space. Interestingly, in the absence of membrane 
which  is  consistent  with  import  and  PARL-mediated  cleav-
age of PINK1 in the inner mitochondrial membrane in the ab-
sence of uncoupling. Although the 52-kD form of PINK1 was 
not functional for Parkin translocation because of its different 
submitochondrial localization compared with CCCP-stabilized 
FL PINK1, this fragment may have other functions within the 
mitochondria. Thus, it will be interesting to determine how this 
fragment is degraded.
Mutagenesis screen of amino acid residues 
affecting PARL-mediated cleavage of PINK1
Rhomboid proteases prefer to cleave specific sequences near 
to transmembrane domains and within membrane-spanning 
helices that are partially destabilized by helix-breaking amino 
acids such as glycine and proline (Urban and Freeman, 2003; 
Strisovsky et al., 2009). Interestingly, the predicted membrane-
spanning region of PINK1 between Ala
93 and Ile
111 contains 
more than one third glycine and proline residues (Fig. 3 a), 
which is consistent with the identified high susceptibility to 
PARL cleavage. Moreover, the PINK1 transmembrane domain 
is highly conserved from zebrafish to human (Fig. S2). Dro-
sophila PINK1 has a predicted transmembrane domain that is 
less homologous to man and contains fewer helix-breaking resi-
dues, suggesting that it may have a different sensitivity to the 
fly PARL orthologue Rhomboid 7 (Fig. S2). To explore PINK1 
cleavage mediated by PARL, we mutated each amino acid in 
this domain to residues with a bulky side chain that we predicted 
may interfere with substrate recognition by PARL. N-terminal 
amino acids 91–98 of the WT PINK1-YFP construct were mutated 
to phenylalanine, and amino acids 99–110 were mutated to 
tryptophan (Fig. 3 a).
HeLa cells transfected with mutant PINK1-YFP constructs 
were either untreated or treated with CCCP or MG132 and ana-
lyzed by immunoblotting (Fig. 3 b). In the absence of CCCP   
or MG132, PINK1-YFP mutants G97F and R98F displayed dra-
matically increased levels of FL and/or MTS-PINK1 (Fig. 3 b,   
green arrowheads; compare control yellow rectangle with red 
rectangles) in contrast to WT and all of the other mutant forms 
of PINK1 (Fig. 3 c). However, in the presence of MG132, G97F 
and R98F PINK1 mutants also displayed partial cleavage to the 
52-kD form (Fig. 3 b, red arrowheads), suggesting that PARL-
mediated PINK1 cleavage was not completely prevented by 
these mutations.
Although WT PINK1-YFP expression is below the level 
of detection, the PINK1-YFP R98F mutant is found localized 
to mitochondria in the absence of CCCP based on subcellular 
fractionation (Fig. S3 a) and confocal imaging (Fig. 3 d). To 
determine the submitochondrial location of PINK1 R98F, a   
mitochondrial PK protection assay was performed. Mitochon-
dria  isolated  from  HeLa  cells  transfected  with  PINK1-YFP 
R98F were treated with increasing amounts of PK, and the deg-
radation pattern of PINK1 R98F was compared with the deg-
radation patterns of mitochondrial proteins representing each 
compartment of mitochondria (Fig. 4 a). PINK1-YFP R98F 
(Fig. 4 a, green arrowhead) exhibited increased protease pro-
tection relative to WT PINK1 (Fig. 2 c), suggesting that the mu-
tant is imported but incompletely processed by PARL-mediated JCB • VOLUME 191 • NUMBER 5 • 2010   938
Figure 3.  Point mutations in the transmembrane domain of PINK1 partially inhibit its proteolytic cleavage. (a) Amino acids throughout the predicted trans-
membrane domain of PINK1 were mutated to phenylalanine (amino acids 91–98) or tryptophan (amino acids 99–110). (b) HeLa cells transfected with the 
indicated PINK1-YFP mutants were treated with either DMSO, 10 µM CCCP, or 10 µM MG132 for 3 h. 20 µg cell lysates were subjected to SDS-PAGE and 
immunoblotting using antibodies against PINK1 and tubulin. (c) The band intensity of FL PINK1 in DMSO- or CCCP-treated lanes from b was densitometrically 
measured using Multi Gauge (Fujifilm). After corrections for background and loading, the band intensity ratio of DMSO/CCCP-treated samples for each 
PINK1 mutant was measured. (d) YFP-tagged WT PINK1 and PINK1 R98F mutants were transfected into HeLa cells. Cells were stained with MitoTracker red 
before treatment with 10 µM CCCP for 3 h and analyzed by confocal microscopy. (bottom) Enlarged views of the boxed areas are shown. Bars, 20 µm.   
Green arrowheads, FL and MTS-PINK1; red arrowheads, 52-kD PINK1.939 m-dependent cleavage of PINK1 mediated by PARL • Jin et al.
Figure 4.  The PINK1 R98F mutant resistant to PARL-mediated cleavage is located inside mitochondria. (a) Mitochondria isolated from HeLa cells trans-
fected with YFP-tagged PINK1 R98F were incubated with various concentrations of PK for 30 min on ice and immunoblotted for PINK1, Tom20, Cyt c, 
AIF, and Hsp70. Green arrowhead, FL and MTS-PINK1; red arrowhead, 52-kD PINK1. (b) HeLa cells transfected with mito-YFP were treated with DMSO 
or 10 µM CCCP for 3 h followed by incubation in either PBS alone or PBS containing 0.005% digitonin or 0.25% Triton X-100 (TX-100). Cells were   
immunostained using antibodies against Tom20 and Cyt c and analyzed by confocal microscopy. (c) HeLa cells were transfected with YFP-tagged WT 
PINK1 or PINK1 R98F mutant for 18 h. Cells were then treated with DMSO or CCCP for 3 h, permeabilized, and immunostained with the indicated   
antibodies. Images were taken by confocal microscopy. (d) HeLa cells (≥150/condition) stained in c were counted for GFP immunofluorescence. Counting 
results were represented as mean ± SEM from four replicates. (e) HeLa cells cotransfected with YFP-tagged PINK1 R98F mutant and mCherry-Parkin were 
incubated with either DMSO or 10 µM CCCP for 1 h followed by confocal imaging. (f) PINK1 KO MEFs transfected with YFP-tagged WT PINK1 or PINK1 
R98F mutant together with mCherry-Pax were treated with DMSO or 10 µM CCCP for 3 h, and cells were counted for mitochondrial translocation of Parkin 
(≥50 cell counts for each sample). Counting results were represented as mean ± SEM from four replicates. Bars, 20 µm.JCB • VOLUME 191 • NUMBER 5 • 2010   940
nonessential amino acids, and penicillin/streptomycin. HeLa cells stably 
expressing YFP-Parkin were grown under selection in 300 µg/ml hygro-
mycin (Sigma-Aldrich). All chemicals for cell culture were purchased from 
Invitrogen. PARL KO and WT MEFs were provided by L. Pellegrini (University 
of Cambridge, Cambridge, England, UK), and PINK1 KO MEFs by Z. Zhang 
(Burnham Institute for Medical Research, La Jolla, CA).
Constructs and mutagenesis
PARL siRNA (5-AAATCCAGGGTCCAGAGTTAT-3’) were synthesized by 
QIAGEN. To achieve efficient knockdown of PARL, cells were transfected 
twice over a period of 96 h. PINK1-V5/His was provided by M. Cookson 
(National Institutes of Health, Bethesda, MD). For site-directed mutagenesis, 
primers were designed using Primer X, a web-based mutagenic primer design 
program (http://www.bioinformatics.org/primerx/), and produced by 
Operon. 15 rounds of PCR reactions were performed using Phusion DNA 
polymerase (Finnzymes) and WT PINK1-YFP constructs as a template. Intro-
duction of point mutations was confirmed by sequencing.
Transfection
Cells were cultured in borosilicated chamber slides for imaging, 6-well 
plates for whole cell lysates, and a 100- or 150-mm culture dish for sub-
cellular fractionation. 1 d after seeding, cells were transfected with the 
potential, Mcr1p is found predominantly on the outer mem-
brane, reflecting our findings with PINK1 (Haucke et al., 1997). 
It seems plausible that additional proteins will be found that 
are regulated by differential mitochondrial membrane targeting. 
Interestingly, expression of FL Oma1 was recently indicated to 
increase on mitochondrial membrane potential collapse, allow-
ing it to accumulate and cleave the mitochondrial fusion protein 
Opa1 (Head at el., 2009). Opa1 degradation by Oma1 may pre-
vent fusion of damaged mitochondria with healthy mitochon-
dria and be coupled to Pink1-mediated recruitment of Parkin to 
facilitate mitophagy.
Materials and methods
Cell culture and chemicals
HeLa cells and MEFs were maintained in DME supplemented with 10%   
fetal calf serum, 20 mM  l-glutamine, 1 mM sodium pyruvate, 1x MEM   
Figure 5.  Model for PINK1 import and processing. OM, outer membrane; IM, inner membrane.941 m-dependent cleavage of PINK1 mediated by PARL • Jin et al.
of R98F mutant PINK1 on mitochondria that do not induce Parkin trans-
location.  Online  supplemental  material  is  available  at  http://www.jcb 
.org/cgi/content/full/jcb.201008084/DC1.
We thank B.P. Head and A.M. van der Bliek for valuable discussions and 
siRNA sequences for proteases, M. Cookson for PINK1-V5/His, B. De Strooper 
for PARL KO and WT MEFs and anti-PARL antibody, and Z. Zhang for PINK1 
MEFs. We also thank S. Banerjee for help with the hydropathy plot.
This work was supported by the National Institutes of Health intra-
mural program.
Submitted: 13 August 2010
Accepted: 27 October 2010
References
Cipolat, S., T. Rudka, D. Hartmann, V. Costa, L. Serneels, K. Craessaerts, K. 
Metzger, C. Frezza, W. Annaert, L. D’Adamio, et al. 2006. Mitochondrial 
rhomboid  PARL  regulates  cytochrome  c  release  during  apoptosis  via 
OPA1-dependent  cristae  remodeling.  Cell.  126:163–175.  doi:10.1016/ 
j.cell.2006.06.021
Clark, I.E., M.W. Dodson, C. Jiang, J.H. Cao, J.R. Huh, J.H. Seol, S.J. Yoo, B.A. 
Hay, and M. Guo. 2006. Drosophila pink1 is required for mitochondrial 
function and interacts genetically with parkin. Nature. 441:1162–1166. 
doi:10.1038/nature04779
Gautier, C.A., T. Kitada, and J. Shen. 2008. Loss of PINK1 causes mitochondrial 
functional defects and increased sensitivity to oxidative stress. Proc. Natl. 
Acad. Sci. USA. 105:11364–11369. doi:10.1073/pnas.0802076105
Geisler,  S.,  K.M.  Holmström,  D.  Skujat,  F.C.  Fiesel,  O.C.  Rothfuss,  P.J. 
Kahle,  and  W.  Springer.  2010.  PINK1/Parkin-mediated  mitophagy  is 
dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 12:119–131. 
doi:10.1038/ncb2012
Greene,  J.C., A.J. Whitworth,  I.  Kuo,  L.A. Andrews,  M.B.  Feany,  and  L.J. 
Pallanck. 2003. Mitochondrial pathology and apoptotic muscle degenera-
tion in Drosophila parkin mutants. Proc. Natl. Acad. Sci. USA. 100:4078–
4083. doi:10.1073/pnas.0737556100
Haucke, V., C.S. Ocana, A. Hönlinger, K. Tokatlidis, N. Pfanner, and G. Schatz. 
1997. Analysis of the sorting signals directing NADH-cytochrome b5 re-
ductase  to  two  locations  within  yeast  mitochondria.  Mol.  Cell.  Biol. 
17:4024–4032.
Head, B., L. Griparic, M. Amiri, S. Gandre-Babbe, and A.M. van der Bliek. 
2009.  Inducible  proteolytic  inactivation  of  OPA1  mediated  by  the 
OMA1 protease in mammalian cells. J. Cell Biol. 187:959–966. doi: 
10.1083/jcb.200906083
Hill, R.B., and L. Pellegrini. 2010. The PARL family of mitochondrial rhom-
boid  proteases.  Semin.  Cell  Dev.  Biol.  21:582–592.  doi:10.1016/ 
j.semcdb.2009.12.011
Kitada, T., S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S. Minoshima, 
M. Yokochi, Y. Mizuno, and N. Shimizu. 1998. Mutations in the parkin 
gene cause autosomal recessive juvenile parkinsonism. Nature. 392:605–
608. doi:10.1038/33416
Lazarou, M., M. McKenzie, A. Ohtake, D.R. Thorburn, and M.T. Ryan. 2007. 
Analysis of the assembly profiles for mitochondrial- and nuclear-DNA-
encoded  subunits  into  complex  I.  Mol.  Cell.  Biol.  27:4228–4237. 
doi:10.1128/MCB.00074-07
Lin, W., and U.J. Kang. 2008. Characterization of PINK1 processing, stability, 
and subcellular localization. J. Neurochem. 106:464–474. doi:10.1111/
j.1471-4159.2008.05398.x
Matsuda, N., S. Sato, K. Shiba, K. Okatsu, K. Saisho, C.A. Gautier, Y.S. Sou,   
S.  Saiki,  S.  Kawajiri,  F.  Sato,  et  al.  2010.  PINK1  stabilized  by  mito-
chondrial depolarization recruits Parkin to damaged mitochondria and 
activates latent Parkin for mitophagy. J. Cell Biol. 189:211–221. doi: 
10.1083/jcb.200910140
Muqit, M.M., P.M. Abou-Sleiman, A.T. Saurin, K. Harvey, S. Gandhi, E. Deas, 
S. Eaton, M.D. Payne Smith, K. Venner, A. Matilla, et al. 2006. Altered 
cleavage and localization of PINK1 to aggresomes in the presence of 
proteasomal stress. J. Neurochem. 98:156–169. doi:10.1111/j.1471-4159 
.2006.03845.x
Narendra, D.P., A. Tanaka, D.F. Suen, and R.J. Youle. 2008. Parkin is recruited 
selectively  to  impaired  mitochondria  and  promotes  their  autophagy.  
J. Cell Biol. 183:795–803. doi:10.1083/jcb.200809125
Narendra, D.P., S.M. Jin, A. Tanaka, D.F. Suen, C.A. Gautier, J. Shen, M.R. 
Cookson, and R.J. Youle. 2010. PINK1 is selectively stabilized on im-
paired mitochondria to activate Parkin. PLoS Biol. 8:e1000298. doi:10 
.1371/journal.pbio.1000298
Palacino, J.J., D. Sagi, M.S. Goldberg, S. Krauss, C. Motz, M. Wacker, J. Klose, 
and J. Shen. 2004. Mitochondrial dysfunction and oxidative damage in 
indicated constructs using Fugene HD (Roche) or Lipofectamine 2000 
(Invitrogen) according to the manufacturers’ guidelines.
Western blotting
For whole cell lysates, cells were washed twice with cold PBS and directly 
lysed with 1× sample buffer. For mitochondrial fraction, cells were fraction-
ated as described previously (Narendra et al., 2008), and mitochondrial 
pellets were lysed with 1× sample buffer. 20 µg proteins was separated 
on 4–12% Tris-glycine or Bis-Tris SDS-PAGE. The following antibodies were 
used in this study: anti-PINK1 (Novus Biologicals), anti-PARL N-terminal 
(provided by L. Pellegrini), anti-Tom20 (Santa Cruz Biotechnology, Inc.), 
anti-AIF (Sigma-Aldrich), and anti-Htra2/Omi (R&D Systems). The following 
polyclonal antibodies were used in this study: anti-VDAC (EMD), anti-tubulin, 
anti–-actin (Sigma-Aldrich), anti-Hsp70 (Cell Signaling Technology), anti-
Tom20 (BD), anti-Tim23, and anti–Cyt c (BD) monoclonal antibodies.
Subcellular fractionation, PK treatment, and alkaline extraction  
of isolated mitochondria
Before fractionation, HeLa cells were treated with 50 µM MG132 for 10 h 
followed by 10 µM CCCP for 3 h to accumulate both FL and 52-kD forms of 
PINK1. Harvested cells were homogenized using a Teflon pestle (Thomas 
Scientific) in 20 mM Hepes-KOH, pH 7.6, 220 mM mannitol, 70 mM 
sucrose, 1 mM EDTA, 0.5 mM PMSF, and 2 mg/ml BSA and centrifuged 
at 800 g at 4°C for 10 min to obtain a postnuclear supernatant. Mitochon-
dria were pelleted by centrifugation at 10,000 g at 4°C for 20 min. The 
supernatant fraction was centrifuged further for 30 min at 100,000 g to 
obtain a cytosolic protein fraction. Cytosolic fractions were concentrated 
using TCA precipitation. Mitochondrial samples treated by alkaline extrac-
tion were resuspended in freshly prepared 0.1 M Na2CO3, pH 11.5, and 
incubated on ice for 30 min with occasional vortexing. Membranes were 
isolated by centrifugation at 100,000 g for 30 min at 4°C and solubilized 
in SDS-PAGE loading dye.
For PK protection assays, mitochondria freshly isolated from HeLa 
cells were resuspended in 20 mM Hepes-KOH, pH 7.4, 250 mM sucrose, 
80 mM KOAc, and 5 mM MgOAc and incubated with various concentra-
tions of PK (Sigma-Aldrich) for 30 min on ice. Digestion was stopped with 
1 mM PMSF followed by TCA precipitation of samples, separation by SDS-
PAGE, and Western blotting.
In vitro import of PINK1 into isolated mitochondria
Generation of radiolabeled PINK1 precursor was performed by in vitro 
transcription followed by translation using rabbit reticulocyte lysates (Pro-
mega) in the presence of [
35S]methionine/cysteine protein-labeling mix 
(PerkinElmer) as previously described (Lazarou et al., 2007). PINK1 trans-
lation products were incubated with freshly isolated mitochondria in import 
buffer (20 mM Hepes-KOH, pH 7.4, 250 mM sucrose, 80 mM KOAc,   
5 mM MgOAc, 5 mM methionine, 1 mM DTT, and 5 mM ATP) at 24°C for 
various times as indicated in Fig. 1 d. Dissipation of membrane potential 
was performed using 1 µM CCCP. Samples subjected to protease treat-
ment were incubated on ice for 10 min in 5 µg/ml PK before protease inac-
tivation with 1 mM PMSF. 50 µg of mitochondrial pellets was precipitated 
using TCA and subjected to SDS-PAGE. Radiolabeled PINK1 was detected 
by digital autoradiography.
Immunocytochemistry and live cell imaging
For immunocytochemistry, cultured cells in borosilicated chamber slides 
were fixed with 4% paraformaldehyde in PBS (USB; Affymetrix) and per-
meabilized with the indicated detergent. After 30 min of blocking with 
10% BSA in PBS, cells were stained with primary antibodies anti-Tom20 
polyclonal antibody (Santa Cruz Biotechnology, Inc.) and anti–Cyt c 
monoclonal antibody (BD) or anti-Tom20 monoclonal antibody (BD) and 
anti-GFP polyclonal antibody (Invitrogen), and were then stained with sec-
ondary antibodies goat anti–mouse or rabbit IgG conjugated with Alexa 
Fluor 594 or 647, respectively. For live cell imaging, cells were pulsed with   
600 nM TMRE for 5 min to evaluate mitochondrial membrane potential or 
10 nM MitoTracker red for 30 min to see the mitochondrial morphology. 
Cells were imaged using an inverted microscope (LSM510 Meta; Carl 
Zeiss, Inc.) with a 63× 1.4 NA oil differential interference contrast Plan 
Apo objective. Image contrast and brightness were adjusted in the accom-
panying image browser (LSM; Carl Zeiss, Inc.).
Online supplemental material
Fig. S1 shows that the transmembrane domain of PINK1 is required for 
accumulation in CCCP and for Parkin recruitment. Fig. S2 shows the se-
quence conservation for predicted PINK1 transmembrane domains from 
various species. Fig. S3 shows the accumulation of FL and MTS forms JCB • VOLUME 191 • NUMBER 5 • 2010   942
parkin-deficient mice. J. Biol. Chem. 279:18614–18622. doi:10.1074/jbc 
.M401135200
Park, J., S.B. Lee, S. Lee, Y. Kim, S. Song, S. Kim, E. Bae, J. Kim, M. Shong, 
J.M. Kim, and J. Chung. 2006. Mitochondrial dysfunction in Drosophila 
PINK1  mutants  is  complemented  by  parkin.  Nature.  441:1157–1161 
. doi:10.1038/nature04788
Plun-Favreau, H., K. Klupsch, N. Moisoi, S. Gandhi, S. Kjaer, D. Frith, K. 
Harvey, E. Deas, R.J. Harvey, N. McDonald, et al. 2007. The mitochon-
drial  protease  HtrA2  is  regulated  by  Parkinson’s  disease-associated   
kinase PINK1. Nat. Cell Biol. 9:1243–1252. doi:10.1038/ncb1644
Pridgeon,  J.W.,  J.A.  Olzmann,  L.S.  Chin,  and  L.  Li.  2007.  PINK1  protects 
against  oxidative  stress  by  phosphorylating  mitochondrial  chaperone 
TRAP1. PLoS Biol. 5:e172. doi:10.1371/journal.pbio.0050172
Shimura, H., N. Hattori, S. Kubo, M. Yoshikawa, T. Kitada, H. Matsumine, S. 
Asakawa, S. Minoshima, Y. Yamamura, N. Shimizu, and Y. Mizuno. 1999. 
Immunohistochemical and subcellular localization of Parkin protein: ab-
sence of protein in autosomal recessive juvenile parkinsonism patients. 
Ann.  Neurol.  45:668–672.  doi:10.1002/1531-8249(199905)45:5<668::
AID-ANA19>3.0.CO;2-Z
Shimura, H., N. Hattori, S. Kubo, Y. Mizuno, S. Asakawa, S. Minoshima, N. 
Shimizu, K. Iwai, T. Chiba, K. Tanaka, and T. Suzuki. 2000. Familial 
Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. 
Genet. 25:302–305. doi:10.1038/77060
Sík, A., B.J. Passer, E.V. Koonin, and L. Pellegrini. 2004. Self-regulated cleavage 
of  the  mitochondrial  intramembrane-cleaving  protease  PARL  yields 
Pbeta,  a  nuclear-targeted  peptide.  J.  Biol.  Chem.  279:15323–15329. 
doi:10.1074/jbc.M313756200
Silvestri, L., V. Caputo, E. Bellacchio, L. Atorino, B. Dallapiccola, E.M. Valente, 
and G. Casari. 2005. Mitochondrial import and enzymatic activity of 
PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 
14:3477–3492. doi:10.1093/hmg/ddi377
Strisovsky, K., H.J. Sharpe, and M. Freeman. 2009. Sequence-specific intra-
membrane proteolysis: identification of a recognition motif in rhomboid 
substrates. Mol. Cell. 36:1048–1059. doi:10.1016/j.molcel.2009.11.006
Takatori, S., G. Ito, and T. Iwatsubo. 2008. Cytoplasmic localization and protea-
somal degradation of N-terminally cleaved form of PINK1. Neurosci. 
Lett. 430:13–17. doi:10.1016/j.neulet.2007.10.019
Tang, B., H. Xiong, P. Sun, Y. Zhang, D. Wang, Z. Hu, Z. Zhu, H. Ma, Q. Pan, 
J.H. Xia, et al. 2006. Association of PINK1 and DJ-1 confers digenic in-
heritance of early-onset Parkinson’s disease. Hum. Mol. Genet. 15:1816–
1825. doi:10.1093/hmg/ddl104
Urban,  S.,  and  M.  Freeman.  2003.  Substrate  specificity  of  rhomboid  intra-
membrane proteases is governed by helix-breaking residues in the sub-
strate transmembrane domain. Mol. Cell. 11:1425–1434. doi:10.1016/ 
S1097-2765(03)00181-3
Urban, S., J.R. Lee, and M. Freeman. 2001. Drosophila rhomboid-1 defines a 
family of putative intramembrane serine proteases. Cell. 107:173–182. 
doi:10.1016/S0092-8674(01)00525-6
Valente,  E.M.,  P.M. Abou-Sleiman, V.  Caputo,  M.M.  Muqit,  K.  Harvey,  S. 
Gispert, Z. Ali, D. Del Turco, A.R. Bentivoglio, D.G. Healy, et al. 2004. 
Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. 
Science. 304:1158–1160. doi:10.1126/science.1096284
Vives-Bauza, C., C. Zhou, Y. Huang, M. Cui, R.L. de Vries, J. Kim, J. May, M.A. 
Tocilescu, W. Liu, H.S. Ko, et al. 2010. PINK1-dependent recruitment of 
Parkin  to  mitochondria  in  mitophagy.  Proc.  Natl.  Acad.  Sci.  USA. 
107:378–383. doi:10.1073/pnas.0911187107
Weihofen, A., B. Ostaszewski, Y. Minami, and D.J. Selkoe. 2008. Pink1 Parkinson 
mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the mat-
uration or subcellular distribution of Pink1. Hum. Mol. Genet. 17:602–
616. doi:10.1093/hmg/ddm334
Whitworth,  A.J.,  J.R.  Lee,  V.M.  Ho,  R.  Flick,  R.  Chowdhury,  and  G.A. 
McQuibban. 2008. Rhomboid-7 and HtrA2/Omi act in a common path-
way with the Parkinson’s disease factors Pink1 and Parkin. Dis. Model 
Mech. 1:168–174. doi:10.1242/dmm.000109
Yang, Y., S. Gehrke, Y. Imai, Z. Huang, Y. Ouyang, J.W. Wang, L. Yang, M.F. 
Beal, H. Vogel, and B. Lu. 2006. Mitochondrial pathology and muscle 
and  dopaminergic  neuron  degeneration  caused  by  inactivation  of 
Drosophila  Pink1  is  rescued  by  Parkin.  Proc.  Natl.  Acad.  Sci.  USA. 
103:10793–10798. doi:10.1073/pnas.0602493103
Zhou, C., Y. Huang, Y. Shao, J. May, D. Prou, C. Perier, W. Dauer, E.A. Schon, 
and S. Przedborski. 2008. The kinase domain of mitochondrial PINK1 
faces  the  cytoplasm.  Proc.  Natl.  Acad.  Sci.  USA.  105:12022–12027. 
doi:10.1073/pnas.0802814105